41982 Federal Register / Vol. 86, No. 147 / Wednesday, August 4, 2021 / Notices 

13This requirement is satisfied by, among other 

things, a certification in basic cardiopulmonary 

resuscitation by an online program that has 

received accreditation from the American Nurses 

Credentialing Center, the ACPE, or the 

Accreditation Council for Continuing Medical 

Education. The phrase ‘‘current certificate in basic 

cardiopulmonary resuscitation,’’ when used in the 

September 3, 2020 or October 20, 2020 OASH 

authorizations, shall be interpreted the same way. 

See Guidance for Licensed Pharmacists and 

Pharmacy Interns Regarding COVID–19 Vaccines 

and Immunity under the PREP Act, OASH, Sept. 3, 

2020, available at https://www.hhs.gov/guidance/ 

sites/default/files/hhs-guidance-documents//

licensed-pharmacists-and-pharmacy-internsregarding-covid-19-vaccines-immunity.pdf (last 

visited Jan. 24, 2021); Guidance for PREP Act 

Coverage for Qualified Pharmacy Technicians and 

State-Authorized Pharmacy Interns for Childhood 

Vaccines, COVID–19 Vaccines, and COVID–19 

Testing, OASH, Oct. 20, 2020, available at https:// 

www.hhs.gov/guidance/sites/default/files/hhsguidance-documents//prep-act-guidance.pdf (last 

visited Jan. 24, 2021). 

podiatry, optometry or veterinary student 

with appropriate training in administering 

vaccines as determined by his or her school 

or training program and supervision by a 

currently practicing healthcare professional 

experienced in administering intramuscular 

injections who administers COVID–19 

vaccines that are Covered Countermeasures 

under section VI of this Declaration in any 

jurisdiction where the PREP Act applies in 

association with a COVID–19 vaccination 

effort by a State, local, Tribal or territorial 

authority or by an institution in which the 

COVID–19 vaccine covered countermeasure 

is administered; 

Subject to the following requirements: 

i. The vaccine must be authorized, 

approved, or licensed by the FDA; 

ii. Vaccination must be ordered and 

administered according to ACIP’s COVID–19 

vaccine recommendation(s); 

iii. The healthcare professionals and 

students must have documentation of 

completion of the Centers for Disease Control 

and Prevention COVID–19 Vaccine Training 

Modules and, if applicable, such additional 

training as may be required by the State, 

territory, locality, or Tribal area in which 

they are prescribing, dispensing, or 

administering COVID–19 vaccines; 

iv. The healthcare professionals and 

students must have documentation of an 

observation period by a currently practicing 

healthcare professional experienced in 

administering intramuscular injections, and 

for whom administering vaccinations is in 

their ordinary scope of practice, who 

confirms competency of the healthcare 

provider or student in preparation and 

administration of the COVID–19 vaccine(s) to 

be administered and, if applicable, such 

additional training as may be required by the 

State, territory, locality, or Tribal area in 

which they are prescribing, dispensing, or 

administering COVID–19 vaccines; 

v. The healthcare professionals and 

students must have a current certificate in 

basic cardiopulmonary resuscitation; 13

vi. The healthcare professionals and 

students must comply with recordkeeping 

and reporting requirements of the 

jurisdiction in which he or she administers 

vaccines, including informing the patient’s 

primary-care provider when available, 

submitting the required immunization 

information to the State or local 

immunization information system (vaccine 

registry), complying with requirements with 

respect to reporting adverse events, and 

complying with requirements whereby the 

person administering a vaccine must review 

the vaccine registry or other vaccination 

records prior to administering a vaccine; and 

vii. The healthcare professionals and 

students comply with any applicable 

requirements (or conditions of use) as set 

forth in the Centers for Disease Control and 

Prevention (CDC) COVID–19 vaccination 

provider agreement and any other federal 

requirements that apply to the administration 

of COVID–19 vaccine(s). 

Nothing in this Declaration shall be 

construed to affect the National Vaccine 

Injury Compensation Program, including an 

injured party’s ability to obtain compensation 

under that program. Covered 

countermeasures that are subject to the 

National Vaccine Injury Compensation 

Program authorized under 42 U.S.C. 300aa– 

10 et seq. are covered under this Declaration 

for the purposes of liability immunity and 

injury compensation only to the extent that 

injury compensation is not provided under 

that Program. All other terms and conditions 

of the Declaration apply to such covered 

countermeasures. 

2. Effective Time Period, section XII, 

delete in full and replace with: 

Liability protections for any respiratory 

protective device approved by NIOSH under 

42 CFR part 84, or any successor regulations, 

through the means of distribution identified 

in Section VII(a) of this Declaration, begin on 

March 27, 2020 and extend through October 

1, 2024. 

Liability protections for all other Covered 

Countermeasures identified in Section VI of 

this Declaration, through means of 

distribution identified in Section VII(a) of 

this Declaration, begin on February 4, 2020 

and extend through October 1, 2024. 

Liability protections for all Covered 

Countermeasures administered and used in 

accordance with the public health and 

medical response of the Authority Having 

Jurisdiction, as identified in Section VII(b) of 

this Declaration, begin with a Declaration of 

Emergency as that term is defined in Section 

VII (except that, with respect to qualified 

persons who order or administer a routine 

childhood vaccination that ACIP 

recommends to persons ages three through 18 

according to ACIP’s standard immunization 

schedule, liability protections began on 

August 24, 2020), and last through (a) the 

final day the Declaration of Emergency is in 

effect, or (b) October 1, 2024, whichever 

occurs first. 

Liability protections for all Covered 

Countermeasures identified in Section VII(c) 

of this Declaration begin on December 9, 

2020 and last through (a) the final day the 

Declaration of Emergency is in effect. or (b) 

October 1, 2024. whichever occurs first. 

Liability protections for Qualified Persons 

under section V(d) of the Declaration who are 

qualified pharmacy technicians and interns 

to administer seasonal influenza vaccine to 

persons aged 19 and older begin on August 

4, 2021. 

Liability protections for Qualified Persons 

under section V(f) of the Declaration begin on 

February 2, 2021, and last through October 1, 

2024. 

Liability protections for Qualified Persons 

under section V(g) of the Declaration begin 

on February 16, 2021, and last through 

October 1, 2024. 

Liability protections for Qualified Persons 

who are physicians, advanced practice 

registered nurses, registered nurses, or 

practical nurses under section V(h) of the 

Declaration begins on February 2, 2021 and 

last through October 1, 2024, with additional 

conditions effective as of March 11, 2021and 

liability protections for all other Qualified 

persons under section V(h) begins on March 

11, 2021 and last through October 1, 2024. 

Authority: 42 U.S.C. 247d–6d. 

Dated: July 30, 2021. 

Xavier Becerra, 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2021–16681 Filed 8–2–21; 11:15 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Fogarty International Center; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Fogarty International 

Center Advisory Board. 

The meeting will be open to the 

public via online meeting. Individuals 

who plan to attend and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Fogarty International 

Center Advisory Board. 

Date: September 9–10, 2021. 

Closed: September 09, 2021, 12:00 p.m. to 

3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 147 / Wednesday, August 4, 2021 / Notices 41983 

Place: Fogarty International Center, 

National Institutes of Health, 31 Center Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Open: September 10, 2021, 12:00 p.m. to 

3:00 p.m. 

Agenda: Update and discussion of current 

and planned Fogarty International Center 

activities. 

Place: Fogarty International Center, 

National Institutes of Health, 31 Center Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Meeting Access: https://www.fic.nih.gov/ 

About/Advisory/Pages/default.aspx. 

Contact Person: Kristen Weymouth, 

Executive Secretary, Fogarty International 

Center, National Institutes of Health, 31 

Center Drive, Room B2C02, Bethesda, MD 

20892–7952, 301–496–1415, 

kristen.weymouth@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: http://

www.fic.nih.gov/About/Advisory/Pages/ 

default.aspx, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.106, Minority International 

Research Training Grant in the Biomedical 

and Behavioral Sciences; 93.154, Special 

International Postdoctoral Research Program 

in Acquired Immunodeficiency Syndrome; 

93.168, International Cooperative 

Biodiversity Groups Program; 93.934, Fogarty 

International Research Collaboration Award; 

93.989, Senior International Fellowship 

Awards Program, National Institutes of 

Health, HHS) 

Dated: July 30, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–16607 Filed 8–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Fellowship: 

Cardiovascular and Respiratory Sciences 

Overflow. 

Date: August 27, 2021. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kimm Hamann, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4118A, 

MSC 7814, Bethesda, MD 20892, (301) 435– 

5575, hamannkj@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: July 30, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–16609 Filed 8–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council on Drug Abuse. 

The meeting will be held as a virtual 

meeting and is open to the public, as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations to view the meeting, 

should notify the Contact Person listed 

below in advance of the meeting. The 

open session will be videocast and can 

be accessed from the NIH Videocasting 

and Podcasting website (http://

videocast.nih.gov/). 

A portion of this will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Drug Abuse. 

Date: September 15, 2021. 

Closed: 11:00 a.m. to 12:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Open: 12:45 p.m. to 4:30 p.m. 

Agenda: Presentations and other business 

of the Council. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Susan R.B. Weiss, Ph.D., 

Director, Division of Extramural Research, 

Office of the Director, National Institute on 

Drug Abuse, NIH, Three White Flint North, 

RM 09D08, 11601 Landsdown Street, 

Bethesda, MD 20852, 301–443–6480, sweiss@

nida.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.drugabuse.gov/NACDA/ 

NACDAHome.html, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: July 29, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–16577 Filed 8–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Heart, Lung, 

and Blood Advisory Council. 

The meeting will be open to the 

public as indicated below and held as 

a virtual meeting. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations to view the meeting, 

should notify the Contact Person listed 

below in advance of the meeting. 


lotter on DSK11XQN23PROD with NOTICES1